Skip to main content

Day: February 20, 2025

Heineken Holding N.V. publishes Annual Report 2024

   Heineken Holding N.V. publishes Annual Report 2024   Amsterdam, 20 February 2025 – Heineken Holding N.V. (EURONEXT: HEIO; OTCQX: HKHHY) today announced that it has published its 2024 Annual Report. The 2024 Annual Report of Heineken Holding N.V. is available at: www.heinekenholding.com              Enquiries    Media Heineken Holding N.V.    Kees Jongsma    tel. +31 6 54 79 82 53    E-mail: cjongsma@spj.nl           Media   InvestorsChristiaan Prins   Tristan van StrienDirector of Global Communications   Global Director of Investor RelationsMarlous den Bieman   Lennart Scholtus / Chris SteynCorporate...

Continue reading

Heineken N.V. publishes combined Financial and Sustainability Annual Report 2024

 Heineken N.V. publishes combined Financial and SustainabilityAnnual Report 2024     Amsterdam, 20 February 2025 – Today we published our Heineken N.V. (“HEINEKEN”) combined Financial and Sustainability Annual Report 2024. We delivered solid results with broad-based growth and profit expansion in 2024. Next to our financial performance, the Annual Report highlights our sustainability impact, marking significant progress on our ambition to Brew a Better World. Furthermore, it is our first Annual Report prepared to comply with the CSRD (EU Corporate Sustainability Reporting Directive) standards, featuring a whole additional range of metrics.   The full Annual Report 2024 is available here: https://www.theheinekencompany.com/our-company/our-2024-annual-report ...

Continue reading

Pulsar Helium Announces Upcoming Down-Hole Testing of the Jetstream Appraisal Wells, Topaz Project, Minnesota, USA

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR TO BE TRANSMITTED, DISTRIBUTED TO, OR SENT BY, ANY NATIONAL OR RESIDENT OR CITIZEN OF ANY SUCH COUNTRIES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION MAY CONTRAVENE LOCAL SECURITIES LAWS OR REGULATIONS. CASCAIS, Portugal, Feb. 20, 2025 (GLOBE NEWSWIRE) — Pulsar Helium Inc. (AIM: PLSR, TSXV: PLSR, OTCQB: PSRHF) (“Pulsar” or the “Company”), a leading helium project development company, is pleased to announce that down-hole testing equipment is scheduled to mobilise to site on Monday, February 24th. The tools consist of an optical televiewer and LithoScanner,...

Continue reading

Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

WALTHAM, Mass. and STOCKHOLM, Sweden, Feb. 20, 2025 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are rare, chronic kidney diseases with no approved treatments. “C3G and IC-MPGN are severe and life-threatening kidney conditions, often leading to kidney failure and requiring a kidney transplant or dialysis for life,” said Lydia Abad-Franch, M.D., head of R&D and medical affairs and chief medical officer at Sobi. “With no approved treatments currently available, this important milestone reflects our dedication to improving outcomes...

Continue reading

AS Tallink Grupp Unaudited Consolidated Interim Report for the Q4 and 12 months of 2024

The results of AS Tallink Grupp for the Q4 and 12 months 2024 will be introduced at an Investor Webinar held today at 12:00 (EEST). To participate, please join via the following link; we kindly ask participants to provide their questions latest by 11:00 am by email to: investor@tallink.ee. Further details are available in a previously published announcement. In the financial year 2024 (1 January – 31 December), AS Tallink Grupp and its subsidiaries (hereinafter referred to as “the Group”) carried 5 580 016 passengers, which is 2.2% less than in the financial year 2023. The number of cargo units transported decreased by 6.4% compared to the previous year amounting to 303 234. The number of passenger vehicles was down by 7.5% year-on-year and amounted to 777 592. The Group’s unaudited consolidated revenue amounted to EUR 785.8 million (EUR...

Continue reading

AS Tallink Grupp Unaudited Consolidated Interim Report for the Q4 and 12 months of 2024

The results of AS Tallink Grupp for the Q4 and 12 months 2024 will be introduced at an Investor Webinar held today at 12:00 (EEST). To participate, please join via the following link; we kindly ask participants to provide their questions latest by 11:00 am by email to: investor@tallink.ee. Further details are available in a previously published announcement. In the financial year 2024 (1 January – 31 December), AS Tallink Grupp and its subsidiaries (hereinafter referred to as “the Group”) carried 5 580 016 passengers, which is 2.2% less than in the financial year 2023. The number of cargo units transported decreased by 6.4% compared to the previous year amounting to 303 234. The number of passenger vehicles was down by 7.5% year-on-year and amounted to 777 592. The Group’s unaudited consolidated revenue amounted to EUR 785.8 million (EUR...

Continue reading

Cnova NV FY24 Earnings & 4Q24 Activity Press release

CNOVA N.V.Full Year financial performance & Fourth Quarter 2024 activity After two years of transformation, 2024 marked a return to growth for Cnova and a significant improvement of operational performance driven by a reinvestment plan with a strong customer-centric approach    Like-for-like1 overall GMV2 gradually returned to growth at the end of 2024, after two years of transformation: –12% in 1Q24, -9% in 2Q24, slightly growing in 3Q24 and +2% in 4Q24, leading to an overall decrease by -5% in FY24 vs. 23, in a challenging environment for Cdiscount’s core markets such as Home (-6%3 vs. 23) and Technical Goods (-1%3 vs. 23) Cdiscount.com Product GMV4 grew by +3% in the 4th quarter 2024 vs. 23, notably thanks to a strong Black Friday performance, and improved quarter after quarter:Vs. 23 1Q24 2Q24...

Continue reading

Kinepolis posts solid annual results thanks to excellent second half of the year

Kinepolis posts solid annual results thanks to excellent second half of the year Regulated information 20 February 2025, 7.00 am CET After a weak first half of the year due to the Hollywood strike, a stronger film offering from June onwards ensured a successful film summer and year-end. As a result, in the second semester, Kinepolis posted its highest revenue and financial result ever for a second half of the year.  However, the second half could not fully compensate for the first five months of the year, so all visitor-related results, for the full year 2024, were at a lower level than the previous year. Revenue per visitor, on the other hand, rose again, both in terms of ticket sales (thanks to investments in and increasing demand for premium formats) and consumption of drinks and snacks. 2024 illustrates that visitor numbers are largely...

Continue reading

TGS announces Q4 2024 results

OSLO, Norway (20 February 2025) – TGS today reports interim financial results for Q4 2024. Financial highlights:Strong contract sales with high OBN activity and an overweight of active streamer vessel capacity allocated to contract work Solid multi-client sales driven by high pre-commitments to ongoing multi-client projects and seasonal uptick in sales from the multi-client library Order inflow of USD 489 million during Q4 2024 – total produced order backlog of USD 749 million Successfully completed a full refinancing of the legacy PGS debt, reduced interest rate of the Senior Secured Notes from 13.5% to 8.5% and realized synergies of approximately USD 35 million Cash flow negatively impacted by non-recurring refinancing items and working capital development Full-year pro-forma organic multi-client investments for 2024 of USD...

Continue reading

Fagron delivers exceptional performance with 14% topline growth and 17% increase in REBITDA for FY 2024

Regulated information – inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 20 February 2025 – 7AM CET Fagron delivers exceptional performance with 14% topline growth and 17% increase in REBITDA for FY 2024 Fagron, the leading global player in pharmaceutical compounding, today publishes its full year results for the period ending 31 December 2024. Key HighlightsExceptional topline performance with 14.3% reported growth (15.9% at CER) and 13.0% organic growth at CER, driven by all regions and segments REBITDA grew 16.8% YoY benefiting from operating leverage, with the margin improving by 50bps to 20.0%, primarily supported by improved operational excellence Operating cash flow of €109.9 million, up 3.3% when adjusted for factoring impact; Leverage ratio remained stable at 1.4x Increased M&A momentum with three acquisitions...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.